share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax制药 | 8-K：重大事件
美股sec公告 ·  05/02 16:05
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc. reported on May 2, 2024, that Dr. Jeffrey Gudin has resigned from his roles as Chief Medical Officer and Executive Vice President. The resignation was not due to any disagreements with the company's operations, policies, or practices. Dr. Gudin will continue to serve as a Class III Director for Virpax Pharmaceuticals. Under the terms of the Separation Agreement, Dr. Gudin will receive a total of $81,900, paid semi-monthly over six months, and will be reimbursed for COBRA coverage for himself and his family for up to six months or until he obtains medical benefits from another employer. Additionally, Dr. Gudin's outstanding stock options will continue to vest as per the company's 2022 Equity Incentive Plan. The Separation Agreement includes a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Virpax Pharmaceuticals, Inc. reported on May 2, 2024, that Dr. Jeffrey Gudin has resigned from his roles as Chief Medical Officer and Executive Vice President. The resignation was not due to any disagreements with the company's operations, policies, or practices. Dr. Gudin will continue to serve as a Class III Director for Virpax Pharmaceuticals. Under the terms of the Separation Agreement, Dr. Gudin will receive a total of $81,900, paid semi-monthly over six months, and will be reimbursed for COBRA coverage for himself and his family for up to six months or until he obtains medical benefits from another employer. Additionally, Dr. Gudin's outstanding stock options will continue to vest as per the company's 2022 Equity Incentive Plan. The Separation Agreement includes a general release of all claims against the company and a mutual non-disparagement clause. The full text of the Separation Agreement is attached to the report as Exhibit 10.1.
Virpax Pharmicals, Inc.于2024年5月2日报告称，杰弗里·古丁博士已辞去首席医疗官兼执行副总裁的职务。辞职不是由于与公司的运营、政策或做法有任何分歧。古丁博士将继续担任Virpax Pharmicals的三类董事。根据离职协议的条款，古丁博士将获得总额为81,900美元的补助，在六个月内每半月支付一次，并将获得为期最多六个月的COBRA保险报销，或者直到他从其他雇主那里获得医疗补助。此外，根据公司2022年股权激励计划，古丁博士的未偿还股票期权将继续归属。分离协议包括对公司的所有索赔的全面解除以及相互不贬低的条款。分居协议的全文作为附录10.1附在报告中。
Virpax Pharmicals, Inc.于2024年5月2日报告称，杰弗里·古丁博士已辞去首席医疗官兼执行副总裁的职务。辞职不是由于与公司的运营、政策或做法有任何分歧。古丁博士将继续担任Virpax Pharmicals的三类董事。根据离职协议的条款，古丁博士将获得总额为81,900美元的补助，在六个月内每半月支付一次，并将获得为期最多六个月的COBRA保险报销，或者直到他从其他雇主那里获得医疗补助。此外，根据公司2022年股权激励计划，古丁博士的未偿还股票期权将继续归属。分离协议包括对公司的所有索赔的全面解除以及相互不贬低的条款。分居协议的全文作为附录10.1附在报告中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息